fda compounding semaglutide update enforcement news Omzo GLP-1 Review 2026: Is This Compounded Telehealth Program Legit GLP-1 Medications – FDA Guidance

Use of GLP1RAs and occurrence of respiratory disorders: A meta-analysis of large randomized trials of GLP1RAs

Furthermore, the data from a phase II study in participants with obesity and MASH presented at the American Diabetes Association showed those on survodutide achieved 18.7% mean weight loss after 46 weeks compared to the placebo group

Long-term use is usually needed to maintain results

[168] In January 2024, a preliminary review conducted by the US Food and Drug Administration (FDA) confirmed no evidence had been found to suggest that the medicine causes suicidal thoughts or actions

When women stop using a GLP-1 in pregnancy in the first trimester, rapid weight regain is possible

Roughly half of users stop within a year, 5 though persistence has improved to 63% when supply and coverage issues are addressed